Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: A randomised, double-blind, placebo-controlled, mechanistic study

Medicine and Dentistry

• Pioglitazone 100%
• Placebo 88%
• Tumor Necrosis Factor 29%
• Enzyme Activity 17%
• Measurement 11%
• Low Drug Dose 11%
• Glucose 11%
• Maturity Onset Diabetes of the Young 11%
• Patient with Type 2 Diabetes 11%
• Glucose Metabolism 11%
• Insulin Resistance 11%
• Insulin Release 11%
• Monocyte Chemotactic Protein 1 11%
• Adiponectin 11%
• Metalloproteinase 11%
• C Reactive Protein 11%
• Plasminogen Activator Inhibitor-1 11%
• Fractalkine 11%
• Patient 11%
• Plasma 11%
• Interleukin-6 11%
• Amaurosis 11%
• Protein Expression 5%
• Insulin 5%
• Glycemic Control 5%
• Hemoglobin A1c 5%
• Skeletal Muscle 5%
• Cell Function 5%
• Adverse Event 5%
• Study Participant 5%
• Insulin Sensitivity 5%
• Sulfonylurea 5%
• Beta Cell 5%
• Glycon 5%
• Resistance Index 5%
• Dipeptidyl Carboxypeptidase 5%
• Insulin Sensitizing Agent 5%
• Muscle Biopsy 5%
• Peroxisome Proliferator Activated Receptor Agonist 5%
• Therapeutic Procedure 5%
• Tissues 5%
• Muscle 5%
• Adipose Tissue 5%
• Anti-Inflammatory Drug 5%
• Muscle Tissue 5%
• Personnel 5%